Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis by Fahed, Akl C. & Nassar, Anwar H.
 Pregnancy in a Woman with Homozygous Familial
Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Fahed, Akl C., and Anwar H. Nassar. 2012. “Pregnancy in a
Woman with Homozygous Familial Hypercholesterolemia Not on
Low-Density Lipoprotein Apheresis.” AJP Reports 2 (1): 33-36.
doi:10.1055/s-0032-1305798. http://dx.doi.org/10.1055/s-0032-
1305798.
Published Version doi:10.1055/s-0032-1305798
Accessed February 19, 2015 2:20:05 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11855730
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAA
Pregnancy in a Woman with Homozygous
Familial Hypercholesterolemia Not on
Low-Density Lipoprotein Apheresis
Akl C. Fahed, M.D. 1 Anwar H. Nassar, M.D. 2
1Department of Genetics, Harvard Medical School, Boston,
Massachusetts
2Department of Obstetrics and Gynecology, American University of
Beirut Medical Center, Beirut, Lebanon
Am J Perinatol Rep 2012;2:33–36.
Address for correspondence and reprint requests Anwar H. Nassar,
M.D., Department of Obstetrics and Gynecology, American University
of Beirut, P.O. Box 113-6044/B36, Beirut, Lebanon
(e-mail: an21@aub.edu.lb).
Case Report
A 24-year-old G2, P1, A0, L1 was clinically diagnosed with
homozygous familial hypercholesterolemia (FH) at the age of
7 based on strong family history (six affected siblings), low-
density lipoprotein (LDL) levels above 500 mg/dL, and pres-
ence of xanthomas and xanthelasmas. Genetic screening of
the family for mutations in LDLR and its promoter, ApoB100,
and PCSK9 as part of an earlier study revealed no mutations.1
Treatment with statins (atorvastatin calcium 20 mg once
daily) and lifestyle modiﬁcations (low-fat diet and daily
exercise) was instated at the age of 19, following which the
xanthomas resolved. The patient had an uneventful smooth
course, full-term pregnancy during that period where she
gave birth to a healthymale by cesarean delivery for failure of
dilation. During this pregnancy, the patient discontinued
statin treatment. The child shows a normal development
and has been disease-free during the ﬁrst 5 years of life. In
2007, the patient was started on LDL apheresis at a rate of two
sessions per month. On LDL apheresis, her total cholesterol
levelwas 591mg/dL, LDL 527mg/dL, high-density lipoprotein
(HDL) 37 mg/dL, and triglycerides 131 mg/dL.
For nonmedical reasons, the patient stopped LDL apheresis
in 2009 and was off any kind of therapy as of 3 months
preconceptionally. At 25 weeks of gestation of that second
pregnancy, she had gained 3.5 kg to a pregestational body
mass index of 23 kg/m2. She also had higher HDL and
triglycerides and lower LDL at 25 weeks (total cholesterol
722 mg/dL, HDL 131 mg/dL, LDL 477 mg/dL, and triglycerides
375 mg/dL) compared with the preconceptional period and
while on LDL apheresis. Cardiovascular assessment was per-
formed at 25 weeks. Echocardiogram showed mild aortic
valve disease (stenosis and regurgitation). Vascular studies
showed a plaque in the origin of the internal carotid arteries
causing less than 50% stenosis bilaterally by carotid duplex
scan. The intimamedia thicknesswas 0.7mmon the right and
1.2 mm on the left side. The ankle-brachial index (ABI) was
0.97 on the right and 0.93 on the left side. ABI is a noninvasive
test of peripheral arterial disease (PAD) in the lower extremi-
ties, performed by measuring blood pressure at the arms and
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Abstract Pregnancy in women with homozygous familial hypercholesterolemia (FH) has been
rarely reported and might pose risks on the mother and her fetus. Although most
reported cases remained on low-density lipoprotein (LDL) apheresis, there are no clear
guidelines regarding the management of this entity. We report the ﬁrst case of an
uncomplicated pregnancy in a 24-year-old homozygous FH woman who was not
maintained on LDL apheresis. FH expresses a wide variability in the phenotype, and
management of homozygous FH cases who desire to become pregnant should be
individualized based on preconceptional assessment with frequent antenatal follow-up.
Decisions on management should be made after weighing the risks versus beneﬁts of
LDL apheresis.
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at the ankles. A normal ABI ranges between 0.9 and 1.3, with
decreased ABI indicating PAD. Obstetric ultrasound showed
measurements commensurate with gestational age with no
gross fetal abnormalities and an estimated fetal weight of 819
g. Fetal echocardiogram showedmild tricuspid regurgitation.
The course of pregnancy was uneventful with normal blood
pressure documented throughout her antenatal care. The
patient had a repeat cesarean delivery at 38 weeks of gesta-
tion and delivered a healthymale infant weighing 3200 g. The
child shows a normal development and is disease free in the
ﬁrst year of life.
Discussion
Homozygous FH is a very rare disease thatmight pose risks on
the mother and her fetus during pregnancy. Animal and
human studies have shown that high maternal cholesterol
increases the risk of fetal and maternal complications during
pregnancy such as growth restriction, preeclampsia, and
abortion.2,3 There are no clear guidelines for themanagement
of these rare cases. Several cases of uncomplicated pregnan-
cies of homozygous FH patients on LDL apheresis are reported
in the literature and accordingly authors recommended its
use.4–7 Only few cases reported complications of LDL aphere-
sis in pregnant FH patients.8 We report the ﬁrst case of an
uneventful pregnancy course in a patient whowas not on LDL
apheresis. Our patient had two uncomplicated pregnancies
off LDL apheresis resulting in two healthy boys. This does not
necessarily suggest that FH patients should not be treated by
apheresis. Nevertheless, such a case should prompt clinicians
toweigh the risks versus beneﬁts of LDL apheresis in pregnant
women. This is particularly important in FH, a disease that has
a great phenotypic variability and whose genotype-pheno-
type correlations are still poorly understood.9 Although this
woman was clinically diagnosed with homozygous FH, ge-
netic screening failed to show a mutation, and her LDL levels
are slightly lower than what would be expected from the
classically described homozygous FH patient in the literature
(between 500 and 1000 mg/dL).
Patients with homozygous FH have premature athero-
sclerosis, which very often is present during childbearing
age. This might affect the uteroplacental circulation leading
to insufﬁciency, which could contribute to the associated
pregnancy complications. The hemodynamic stress during
pregnancy may exacerbate preexisting cardiovascular le-
sions and precipitate acute events, to an extent that some
reported homozygous FH as a contraindication for pregnan-
cy.10 Therefore, detailed preconceptional cardiovascular
assessment should be performed on women who desire
to become pregnant, and this should guide their manage-
ment. In our case, the patient had only mild aortic and
carotid disease, which does not usually result in vascular
insufﬁciency.
Lipid changes during pregnancy have been studied in both
normal patients and patients with FH. Physiological lipopro-
tein changes in a normal pregnancy are due to the effects of
estrogen and progesterone on lipoprotein metabolism and
are characterized by an increased LDL and triglycerides
throughout and a decreased HDL in the third trimester.7
Homozygous FH women who desire to become pregnant
are at risk of increased exposure to LDL cholesterol due to
this unfavorable lipoprotein proﬁle and the need to stop
statin therapy, both superimposed on their hypercholesterol-
emic baseline. In our patient, triglycerides and HDL increased
and her LDL decreased despite stopping statins and LDL
apheresis. Normalization of LDL during pregnancy has been
reported before in a heterozygous FH patient,11 and studies
on an animal model of FH showed similar results suggesting
an increase in LDL receptor activity during pregnancy.12 The
mutation status of the patient might play a role in the
response of lipid metabolism to the hormonal changes of
pregnancy. More studies will need to be done to further
elucidate the details of the pathways involved. Until then,
physicians should individualize the care of women with
homozygous FH who desire to get pregnant and weigh the
risks versus beneﬁts of LDL apheresis. A detailed preconcep-
tional assessment and frequent follow-up of lipid proﬁle,
cardiovascular status, and the fetus should help guide man-
agement decisions.
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